56 completed, 9 terminated, 9 unknown, 4 not yet recruiting. 85 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 85 | Completed 56, Terminated 9, Unknown 9, Not yet recruiting 4, Withdrawn 4, Recruiting 3 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children Urgent PC - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | Chi Dang Hornik | 50 | 2027-04-01 | 2026-06-17 |
| Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease mirabegron, Exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 4 | Not yet recruiting | VA Office of Research and Development | 146 | 2026-11-09 | 2026-10-27 |
| The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder Intravesical Botox injection - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Withdrawn | University Hospitals Cleveland Medical Center | 2026-06-01 | 2025-09-05 | |
| A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection, Sham Mask - Overactive Bladder, Neurogenic Bladder | Phase 4 | Not yet recruiting | TriHealth Inc. | 96 | 2026-02-01 | 2026-02-04 |
| Prophylactic Analgesia for Bladder Botox Injections Phenazopyridine, 1% lidocaine with sodium bicarbonate - Urinary Incontinence, Urinary Incontinence, Urge | Phase 4 | Withdrawn | Montefiore Medical Center | 2025-07-01 | 2025-07-18 | |
| Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections Lidocaine 2% without vessel constrictor - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | University of Louisville | 36 | 2024-12-01 | 2024-11-19 |
| Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women vaginal 17 beta-estradiol, Placebo, Behavioral modifications - Lower Urinary Tract Symptoms, Female Genitourinary Disease | Phase 4 | Completed | Mahidol University | 86 | 2024-04-08 | 2025-04-20 |
| Bladder Botox UTI Antibiotic Prophylaxis Nitrofurantoin 100 MG - Overactive Bladder, Bladder Pain Syndrome | Phase 4 | Recruiting | Walter Reed National Military Medical Center | 100 | 2024-04-04 | 2025-02-19 |
| Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection Single-Dose Antibiotic, Multi-Dose Antibiotic - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Completed | The Cleveland Clinic | 100 | 2022-12-06 | 2024-01-02 |
| TReating Incontinence for Underlying Mental and Physical Health Tolterodine Tartrate ER, Mirabegron, Placebo - Urinary Incontinence, Urge, Urinary Incontinence | Phase 4 | Recruiting | University of California, San Francisco | 270 | 2022-10-04 | 2026-03-06 |
| Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study mirabegron - Overactive Bladder | Phase 4 | Unknown | Peking Union Medical College Hospital | 600 | 2022-07-15 | 2022-07-11 |
| Procedural Discomfort Related to Number of Intradetrusor Botox Injections Intradetrusor Botox Injections - Overactive Bladder | Phase 4 | Completed | The Methodist Hospital Research Institute | 108 | 2022-07-07 | 2025-04-13 |
| Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial OnabotulinumtoxinA 100 UNT [Botox] - Overactive Bladder, Urinary Urge Incontinence | Phase 4 | Completed | University of California, Irvine | 116 | 2022-05-01 | 2026-02-25 |
| Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial OnabotulinumtoxinA - Overactive Bladder Syndrome, Overactive Bladder | Phase 4 | Unknown | Augusta University | 100 | 2022-01-01 | 2021-12-15 |
| Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia. Mirabegron, Tamsulosin - Overactive Bladder, Benign Prostatic Hyperplasia | Phase 4 | Unknown | St. Joseph's Healthcare Hamilton | 200 | 2021-12-01 | 2021-03-19 |
| Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB Tadalafil 5mg, Tamsulosin Hcl 0.4 mg, solifenacin 10 mg - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Unknown | Mansoura University | 60 | 2021-11-08 | 2022-08-10 |
| Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study) Mirabegron 50 MG, Posterior Tibial Nerve Stimulation (PTNS) - Overactive Bladder | Phase 4 | Completed | University of Alabama at Birmingham | 54 | 2021-10-01 | 2023-07-20 |
| Minimizing Pain During Office Intradetrussor Botox Injection Bicarbonate protocol, Standard protocol - Overactive Bladder, Overactive Detrusor | Phase 4 | Completed | Boston Urogynecology Associates | 85 | 2020-08-15 | 2025-03-06 |
| Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome Tolterodine Tartrate 4 MG, Continuous positive airway pressure therapy (CPAP) - Overactive Bladder, Obstructive Sleep Apnea | Phase 4 | Completed | Yuzuncu Yil University | 60 | 2020-06-01 | 2022-02-22 |
| Is 10 Injections of Bladder Botox Less Painful Than 20 Injections? OnabotulinumtoxinA 100 Units - Overactive Bladder | Phase 4 | Completed | Wake Forest University Health Sciences | 41 | 2019-11-10 | 2024-04-17 |
Showing 20 of 85. Sign in to see all of them.
Urinary Bladder, Overactive (85) · Urinary Incontinence, Urge (15) · Urinary Incontinence (10) · Prostatic Hyperplasia (9) · Lower Urinary Tract Symptoms (6) · Parkinson Disease (3) · Urinary Bladder, Neurogenic (3) · Agnosia (2) · Cystitis, Interstitial (2) · Nocturia (2) · Pain (2) · Urinary Tract Infections (2) · Xerostomia (2) · Cognition Disorders (1) · Constipation (1)
Female Urogenital Diseases and Pregnancy Complications (85) · Male Urogenital Diseases (85) · Pathological Conditions, Signs and Symptoms (85) · Signs and Symptoms (85) · Urogenital Diseases (85) · Urological Manifestations (85) · Female Urogenital Diseases (84) · Urinary Bladder Diseases (84) · Urologic Diseases (84) · Lower Urinary Tract Symptoms (79) · Urination Disorders (21) · Urinary Incontinence (11) · Nervous System Diseases (10) · Genital Diseases (9) · Genital Diseases, Male (9)
Solifenacin Succinate (20) · mirabegron (15) · Botulinum Toxins, Type A (8) · Tolterodine Tartrate (8) · fesoterodine (8) · Tamsulosin (7) · trospium chloride (4) · Lidocaine (3) · oxybutynin (3) · Estrogens (2) · onabotulinum toxin A (2) · AIEOP acute lymphoblastic leukemia protocol (1) · Adrenergic beta-3 Receptor Agonists (1) · Anti-Bacterial Agents (1) · Antibiotic Prophylaxis (1)
Astellas Pharma Inc (7) · Allergan (6) · Samsung Medical Center (6) · Pfizer (3) · KYU-SUNG LEE (2) · Loyola University (2) · Peking Union Medical College Hospital (2) · Seoul National University Hospital (2) · The Cleveland Clinic (2) · University of California, San Francisco (2) · Uroplasty, Inc (2) · Wake Forest University Health Sciences (2) · Walter Reed National Military Medical Center (2) · Adana Numune Training and Research Hospital (1) · Asan Medical Center (1)
United States (45) · South Korea (17) · Canada (6) · Czechia (4) · France (4) · Italy (4) · Poland (4) · Turkey (Türkiye) (4) · United Kingdom (4) · Germany (3) · Hungary (3) · Japan (3) · Russia (3) · Spain (3) · Taiwan (3)
Kyu-Sung Lee, Ph.D (7) · Alan Wolfe, PhD (2) · Rose Khavari, MD (2) · Ahana Gaurav (1) · Ahmed Elhefnawy (1) · Alexandriah Alas, MD (1) · Alison Huang, MD, MAS, MPhil (1) · Angela DiCarlo-Meacham, MD (1) · Anil Kapoor, MD, FRCSC (1) · Carly Crowder, MD (1) · Catherine Matthews, MD (1)
PMID 37160401, PMID 10435146, PMID 10775736, PMID 15712851, PMID 17132474, PMID 17187655, PMID 17983434, PMID 19912183, PMID 20690893, PMID 21175373, PMID 21532512, PMID 21684773, PMID 22840868, PMID 23973522, PMID 24415559, PMID 24552358, PMID 24792229, PMID 25363606, PMID 25401784, PMID 29324595, PMID 32665528, PMID 32791124, PMID 33208652, PMID 33245533, PMID 34807883, PMID 35412069, PMID 35881009, PMID 37085880, PMID 37811598, PMID 37991564, PMID 38484251, PMID 39101958, PMID 40025238
2008 (1), 2015 (1), I01RD000466 (1), R01AG075471 (1)